07:27 AM EDT, 10/05/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) completed a $2 billion equity investment in US-based biopharmaceutical oncology company Summit Therapeutics. The UK-headquartered biopharmaceutical company's investment will accelerate the development of first-in-class bispecific antibody ivonescimab plus antibody-drug conjugates across various tumor types, according to a Monday release. Under the deal, AstraZeneca agreed to purchase 109,000 preferred shares convertible into common stock, with the investment giving it rights equivalent to 12% of Summit's outstanding common stock, or 10.6% on a fully diluted basis.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.